

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

B&K CORPORATION LIMITED
青城新藥生物科技（青島）股份有限公司

(formerly known as 華芒生物科技（青島）股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2396)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of B&K Corporation Limited (the “**Company**”) hereby announces that a meeting of the Board of the Company will be held on Friday, 14 August 2026 for the purpose of considering and approving the announcement of interim results of the Company and its subsidiaries for six months ended 30 June 2026 and the payment of an interim dividend, if any, and transacting any other business.

By Order of the Board
B&K Corporation Limited
Ms. JIA Lijia
Chairperson and Executive Director

Qingdao, the PRC
4 August 2026

As of the date of this announcement, the Board comprises (i) Ms. JIA Lijia, Mr. WANG Kelong, Dr. ZHAI Junhui and Mr. MIAO Tianxiang as executive directors; (ii) Ms. LIN Ying and Mr. YUAN Fei as non-executive directors; and (iii) Mr. FOK Chi Tat Michael, Mr. LI Jiayan and Mr. YUE Yichun as independent non-executive directors.